title: Case studies showing clinical signs and management of cutaneous  toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients  with solid tumours.
authors.affiliation: Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. i.desar@AIG.umcn.nl
authors.forename: Ingrid M E
authors.initials: IM
authors.lastname: Desar
authors.forename: H Jorn
authors.initials: HJ
authors.lastname: Bovenschen
authors.forename: Anja J N H
authors.initials: AJ
authors.lastname: Timmer-Bonte
authors.forename: Mireille V
authors.initials: MV
authors.lastname: Cantarini
authors.forename: Winette T A
authors.initials: WT
authors.lastname: Van Der Graaf
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Van Rossum
authors.forename: Carla M L
authors.initials: CM
authors.lastname: Van Herpen
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D004791:Enzyme Inhibitors / Q000009:adverse effects; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors; D048730:MAP Kinase Kinase Kinase 2 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012871:Skin Diseases / Q000139:chemically induced*
chemical_list: C517975:AZD 6244; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D048730:MAP Kinase Kinase Kinase 2; D048369:MAP Kinase Kinase 1